Autism Biomarkers Consortium for Clinical Trials - James McPartland PhD, Yale @Synchrony2020

The Autism Biomarkers Consortium for Clinical Trials (ABC-CT) evaluated the viability of a battery of EEG and eye-tracking (ET) assays of social communication in ASD for use in clinical trials. The study enrolled 280 rigorously characterized children with ASD (6-11 years; IQ 60-150) and 119 typically developing (TD) control subjects. Two biomarkers, the EEG-based N170 to Upright Human Faces and the ET-based Oculomotor Index of Gaze to Human Faces have been accepted into the FDA’s Center for Drug Evaluation and Research Biomarker Qualification Program.

This lecture reviews ABC-CT study design and results of the first study and provides an overview of the planned second phase of the study.

#biomarkers #clinicaltrials #FDA

This talk was part of first day of Synchrony 2020 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.